



23 October 2018

EKF Diagnostics Holdings plc
("EKF" or the "Company")

Update to distribution timetable

Following the release of the Company's announcement on 22 October 2018, the Company provides the below update in relation to its planned distribution timetable.

The updated anticipated timetable for the distribution is set out below:

	2018
Record date for the Distribution	Close of business on 23 October
EKF ordinary shares marked as ex rights	8.00am on 24 October
Distribution declared by the board of directors	24 October
Admission of issued and to be issued RENX Shares to trading on AIM	2 November
	2019
End of Lock-up Period	22 April

EKF shareholders on the register at close of business on 23 October 2018 ("Relevant EKF Shareholders") will receive one RENX Share for every 21.825 EKF ordinary shares held.

All times and dates in this announcement may be subject to change.

Enquiries:

EKF Diagnostics Holdings plc

Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, FD & COO

Tel: 029 2071 0570

N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)

Tel: 020 7496 3000

Walbrook PR Limited

Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or ekf@walbrookpr.com

Mob: 07980 541 893 / 07584 391 303

About EKF Diagnostics Holdings plc www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.